Revolutionizing Pediatric Dermatology: Dupilumab’s Impact on Atopic Dermatitis in Kids
DOI:
https://doi.org/10.54536/ajlsi.v3i1.2696Keywords:
Atopic Dermatitis, Pediatrics, Dupilumab, Immunosuppressants, Monoclonal Antibodies CorticosteroidsAbstract
Eczema, or atopic dermatitis, is a common, non-communicable, immune-mediated, inflammatory skin illness mainly affecting children. It is a chronic condition. It causes mental health problems like anxiety, sadness, anxiety, depression, hyperactivity, and obesity. It is the first skin ailment and the fifteenth non-fatal disease. The purpose of the present research study was to evaluate the Safety and Effectiveness of biological treatment for atopic dermatitis using monoclonal antibodies against non-biological treatment, including antibiotics, immunosuppressants, demards, histamine antagonists and corticosteroids. Patient information was gathered from FDA-approved clinical trials. The comparative analysis found that Biological therapies like Dupilumab, Omalizumab, and Ustekinumab improve symptoms and disease control in atopic dermatitis. Non-biological treatments may not be as effective. Early antibiotic exposure can increase infection vulnerability. Mild eczema infections require biological agents. Topical corticosteroids can be combined with Dupilumab for effective treatment of atopic dermatitis. Studies show that Dupilumab improves symptoms and quality of life, making it a better option than a placebo. FDA recommends using biological agents over immunosuppressants in paediatrics for improved immune results. FDA clinical trials showed that dupilumab is a safe and effective treatment for children with moderate-to-severe atopic dermatitis, reducing disease severity and improving quality of life in young AD patients.
Downloads
References
Albrecht, M., & Dittrich, A. (2015). Expression and function of histamine and its receptors in atopic dermatitis. Molecular and cellular pediatrics, 2, 1-8.
Amber, T., & Tabassum, S. (2020). Cyclosporin in dermatology: A practical compendium. Dermatologic Therapy, 33(6), e13934.
Anderson III, W. C., & Szefler, S. J. (2019). Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: to biologic or not to biologic? Annals of Allergy, Asthma & Immunology, 122(4), 367-372.
Antti, A., Salava, A., Perälä, M., Pelkonen, A. S., Mäkelä, M. J., & Remitz, A. (2021). Are infants and toddlers with moderate-to-severe atopic dermatitis undertreated? Experiences of a Finnish tertiary care hospital. Acta Dermato-Venereologica, 101(1).
Axon, E., Chalmers, J. R., Santer, M., Ridd, M. J., Lawton, S., Langan, S. M., Grindlay, D. J., Muller, I., Roberts, A., & Ahmed, A. (2021). Safety of topical corticosteroids in atopic eczema: an umbrella review. BMJ open, 11(7), e046476.
Berna-Rico, E., Fiz-Benito, E., Busto-Leis, J. M., Servera-Negre, G., de Lucas-Laguna, R., & Feito-Rodriguez, M. (2023). Effectiveness and safety of dupilumab in children under 6 years of age with moderate-to-severe atopic dermatitis: a retrospective real-world study. Dermatology, 1-1.
Berth-Jones, J., Damstra, R. J., Golsch, S., Livden, J. K., Van Hooteghem, O., Allegra, F., & Parker, C. A. (2003). Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. Bmj, 326(7403), 1367.
Bohannon, M., Liu, M., Nadeau, P., Talton, J., Gibson, D., Datta, S., Schultz, G., Talton, J., & De Benedetto, A. (2020). Topical doxycycline monohydrate hydrogel 1% targeting proteases/PAR2 pathway is a novel therapeutic for atopic dermatitis. Experimental dermatology, 29(12), 1171-1175.
Caffarelli, C., Giannetti, A., Giannì, G., & Ricci, G. (2023). Anti-inflammatory and biologic drugs for atopic dermatitis: a therapeutic approach in children and adolescents. Frontiers in Medicine, 10.
Choi, C. W., Yang, B. R., Suh, D. I., Kim, M. S., Ohn, J., Hong, J. S., Lee, J., & Kim, K. H. (2020). Infection, antibiotic exposure and development of atopic dermatitis: A nationwide case–control study. The Journal of dermatology, 47(7), 707-713.
Chovatiya, R., & Silverberg, J. I. (2019). Pathophysiology of atopic dermatitis and psoriasis: implications for management in children. Children, 6(10), 108.
Chu, A. W., Wong, M. M., Rayner, D. G., Guyatt, G. H., Martinez, J. P. D., Ceccacci, R., Zhao, I. X., McMullen, E., Srivastava, A., & Wang, J. (2023). Systemic treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials. Journal of Allergy and Clinical Immunology, 152(6), 1470-1492.
Class, I., Class, I., & Class, I. (2022). Systemic antibiotic prophylaxis for recurrent infective flares in children and adolescents with atopic dermatitis. Ann Acad Med Singap, 51(2), 113-114.
Cork, M. J., Danby, S. G., Rossi, A. B., & Bansal, A. (2024). Dupilumab Treatment in Pediatric Patients Aged 6–11 Years with Severe Atopic Dermatitis Whose Disease Is Not Adequately Controlled: A Review. Drug Design, Development and Therapy, 277-289.
Coskey, R. J. (1978). Contact dermatitis due to clindamycin. Archives of Dermatology, 114(3), 446-446.
Deleanu, D., & Nedelea, I. (2019). Biological therapies for atopic dermatitis: An update. Experimental and therapeutic medicine, 17(2), 1061-1067.
Dhamija, S., Patel, R., Pol, S. A., Kulkarni, S., & Yamagar, N. (2024). Comparing Treatment Outcome of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray and Nasal Douching. Journal of Clinical Otorhinolaryngology, 6(1).
Drucker, A., Eyerich, K., de Bruin‐Weller, M., Thyssen, J. P., Spuls, P., Irvine, A., Girolomoni, G., Dhar, S., Flohr, C., & Murrell, D. (2018). Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. British Journal of Dermatology, 178(3), 768-775.
Drug Trials Snapshots: DUPIXENT (2017). Food And Drug Administration.
FDA. (2019). BLA Multi-Disciplinary review and Evaluation. Food and drug administration.
Ferrucci, S. M., Tavecchio, S., Marzano, A. V., & Buffon, S. (2023). Emerging systemic treatments for atopic dermatitis. Dermatology and Therapy, 13(5), 1071-1081.
Frazier, W., & Bhardwaj, N. (2020). Atopic dermatitis: diagnosis and treatment. American family physician, 101(10), 590-598.
Grobe, W., Bieber, T., & Novak, N. (2019). Pathophysiology of atopic dermatitis. JDDG: Journal der deutschen dermatologischen Gesellschaft, 17(4), 433-440.
Haeck, I. M., Rouwen, T. J., Timmer-de Mik, L., de Bruin-Weller, M. S., & Bruijnzeel-Koomen, C. A. (2011). Topical corticosteroids in atopic dermatitis and the risk of glaucoma and cataracts. Journal of the American Academy of Dermatology, 64(2), 275-281.
Harvey, J., Lax, S. J., Lowe, A., Santer, M., Lawton, S., Langan, S. M., Roberts, A., Stuart, B., Williams, H. C., & Thomas, K. S. (2023). The long‐term safety of topical corticosteroids in atopic dermatitis: A systematic review. Skin Health and Disease, 3(5), e268.
Hon, K. L. E., Chan, V. P., & Leung, A. K. (2021). Experimental drugs with the potential to treat atopic eczema. Journal of experimental pharmacology, 487-498.
Hulme, J. (2023). Staphylococcus Infection: Relapsing Atopic Dermatitis and Microbial Restoration. Antibiotics, 12(2), 222.
Kamal, M. A., Kovalenko, P., Kosloski, M. P., Srinivasan, K., Zhang, Y., Rajadhyaksha, M., Lai, C. H., Kanamaluru, V., Xu, C., & Sun, X. (2021). The posology of dupilumab in pediatric patients with atopic dermatitis. Clinical Pharmacology & Therapeutics, 110(5), 1318-1328.
Kamphuis, E., Boesjes, C. M., Loman, L., Bakker, D. S., Poelhekken, M., Zuithoff, N. P., Kamsteeg, M., Romeijn, G. L., van Wijk, F., & de Bruin‐Weller, M. S. (2022). Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28‐week clinical and biomarker results from the BioDay registry. Pediatric Allergy and Immunology, 33(12), e13887.
Kim, J., Kim, B. E., & Leung, D. Y. (2019). Pathophysiology of atopic dermatitis: Clinical implications. Allergy and asthma proceedings,
Kraft, M., & Worm, M. (2017). Dupilumab in the treatment of moderate-to-severe atopic dermatitis. Expert review of clinical immunology, 13(4), 301-310.
Lee, J. H., Yun, S.-J., Lee, J.-B., & Lee, S.-C. (2020). Therapeutic efficacy and safety of methotrexate in moderate-to-severe atopic dermatitis: a retrospective study of Korean patients at tertiary referral hospital. Annals of Dermatology, 32(5), 402.
Li, Y., Jing, D., Huang, Y., Su, J., Li, J., Li, J., Tao, J., Shan, S., Wang, X., & Kang, X. (2021). Association of antibiotics use in preschool age with atopic and allergic skin diseases in young adulthood: a population-based retrospective cohort study. BMJ open, 11(9), e047768.
Mandlik, D. S., & Mandlik, S. K. (2021). Atopic dermatitis: new insight into the etiology, pathogenesis, diagnosis and novel treatment strategies. Immunopharmacology and immunotoxicology, 43(2), 105-125.
Martins, J. C., Martins, C., Aoki, V., Gois, A. F., Ishii, H. A., & da Silva, E. M. (2015). Topical tacrolimus for atopic dermatitis. Cochrane Database of Systematic Reviews(7).
Megna, M., Napolitano, M., Patruno, C., Villani, A., Balato, A., Monfrecola, G., Ayala, F., & Balato, N. (2017). Systemic treatment of adult atopic dermatitis: a review. Dermatology and Therapy, 7, 1-23.
Mehta, Y., & Fulmali, D. G. (2022). Relationship between atopic dermatitis and food allergy in children. Cureus, 14(12).
Montes-Torres, A., Llamas-Velasco, M., Pérez-Plaza, A., Solano-López, G., & Sánchez-Pérez, J. (2015). Biological treatments in atopic dermatitis. Journal of Clinical Medicine, 4(4), 593-613.
Mose, A. P., Usamah, A., & Svedman, C. (2022). Allergic contact dermatitis to topical clindamycin in a patient with hidradenitis suppurativa. Acta Dermato-Venereologica, 102.
Mubanga, M., Lundholm, C., D’Onofrio, B. M., Stratmann, M., Hedman, A., & Almqvist, C. (2021). Association of early life exposure to antibiotics with risk of atopic dermatitis in Sweden. JAMA Network open, 4(4), e215245-e215245.
Nakahara, T., Kido‐Nakahara, M., Tsuji, G., & Furue, M. (2021). Basics and recent advances in the pathophysiology of atopic dermatitis. The Journal of dermatology, 48(2), 130-139.
Napolitano, M., Fabbrocini, G., Neri, I., Stingeni, L., Boccaletti, V., Piccolo, V., Amoruso, G. F., Malara, G., De Pasquale, R., & Di Brizzi, E. V. (2022). Dupilumab treatment in children aged 6–11 years with atopic dermatitis: a multicentre, real-life study. Pediatric Drugs, 24(6), 671-678.
Neri, L. (2015). Antibiotic therapy in the management of atopic dermatitis. Giornale italiano di dermatologia e venereologia: organo ufficiale, Societa italiana di dermatologia e sifilografia, 150(3), 321-325.
Nicholas, M. N., Keown-Stoneman, C. D., Maguire, J. L., & Drucker, A. M. (2022). Association between atopic dermatitis and height, body mass index, and weight in children. JAMA dermatology, 158(1), 26-32.
Ohsawa, Y., & Hirasawa, N. (2014). The role of histamine H1 and H4 receptors in atopic dermatitis: from basic research to clinical study. Allergology International, 63(4), 533-542.
Paolino, A., Alexander, H., Broderick, C., & Flohr, C. (2023). Non‐biologic systemic treatments for atopic dermatitis: current state of the art and future directions. Clinical & Experimental Allergy, 53(5), 495-510.
Papp, K. A., Hong, C.-h., Lansang, M. P., Turchin, I., Adam, D. N., Beecker, J. R., Bissonnette, R., Gooderham, M. J., Jack, C., & Joseph, M. (2021). Practical management of patients with atopic dermatitis on dupilumab. Dermatology and Therapy, 11, 1805-1828.
Phan, K., & Smith, S. D. (2020). Mycophenolate mofetil and atopic dermatitis: systematic review and meta-analysis. Journal of Dermatological Treatment, 31(8), 810-814.
Rajagopalan, M., Saraswat, A., Chandrashekar, B. S., Dhar, S., Dogra, S., Tahiliani, S., & Raj, P. (2022). Role of cyclosporine (CsA) in immuno-dermatological conditions. Indian Dermatology Online Journal, 13(5), 585-599.
Rist, T., Parish, L., Capin, L., Sulica, V., Bushnell, W., & Cupo, M. (2002). A comparison of the efficacy and safety of mupirocin cream and cephalexin in the treatment of secondarily infected eczema. Clinical and experimental dermatology, 27(1), 14-20.
Rusiñol, L., & Puig, L. (2024). Multi-Omics Approach to Improved Diagnosis and Treatment of Atopic Dermatitis and Psoriasis. International Journal of Molecular Sciences, 25(2), 1042.
Schaper‐Gerhardt, K., Rossbach, K., Nikolouli, E., Werfel, T., Gutzmer, R., & Mommert, S. (2020). The role of the histamine H4 receptor in atopic dermatitis and psoriasis. British journal of pharmacology, 177(3), 490-502.
Shah, N., Alhusayen, R., Walsh, S., & Shear, N. H. (2018). Methotrexate in the treatment of moderate to severe atopic dermatitis: a retrospective study. Journal of cutaneous medicine and surgery, 22(5), 484-487.
Soares, G. B., Hashimoto, T., & Yosipovitch, G. (2024). Atopic Dermatitis Itch: Scratching for an Explanation. Journal of Investigative Dermatology.
Sonya Kahn, M., Rind, D., Chapman, R., Kumar, V., Kahn, S., & Carlson, J. (2018). Economic evaluation of dupilumab for moderate-to-severe atopic dermatitis: a cost-utility analysis. J Drugs Dermatol, 17(7), 750-756.
Stacey, S. K., & McEleney, M. (2021). Topical corticosteroids: choice and application. American family physician, 103(6), 337-343.
Study of Dupilumab. (2017). Clinical trials. gov.
Subramanian, I., Singh, V. K., & Jere, A. (2018). Elucidating mechanistic insights into drug action for atopic dermatitis: a systems biology approach. BMC dermatology, 18, 1-12.
Umar, B. U., Rahman, S., Dutta, S., Islam, T., Nusrat, N., Chowdhury, K., Ahmad, W. F. S. B. W., Haque, M., Umar, B. U. U., & Fakuradzi, W. F. S. W. A. (2022). Management of atopic dermatitis: the role of tacrolimus. Cureus, 14(8).
Xu, X., van Galen, L. S., Koh, M. J. A., Bajpai, R., Thng, S., Yew, Y. W., Ho, V. P. Y., Alagappan, U., Järbrink, K. S. A., & Car, J. (2019). Factors influencing quality of life in children with atopic dermatitis and their caregivers: a cross-sectional study. Scientific Reports, 9(1), 15990.
Zhou, S., Qi, F., Gong, Y., Zhang, J., & Zhu, B. (2021). Biological therapies for atopic dermatitis: a systematic review. Dermatology, 237(4), 542-552.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Eiman Hamza Ahmed Elsayed, Rabab Elsayed Ali Hassan Khater
This work is licensed under a Creative Commons Attribution 4.0 International License.
